Tune Therapeutics

Tune Therapeutics is a leading epigenome editing company developing gene, cell, and regenerative therapies using its TEMPO platform. Their focus is on treating common and chronic diseases, with a current clinical-stage drug (Tune-401) for chronic Hepatitis B. The company aims to expand the application of epigenetic therapies.

Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $175M

Date: 12-Jan-2025

Investors: New Enterprise Associates, Yosemite, Regeneron Ventures, Hevolution Foundation

Markets: Biotechnology, Gene Therapy, Epigenome Editing, Health Care, Therapeutics

HQ: Durham, North Carolina, United States

Founded: 2020

Website: https://tunetx.com/

LinkedIn: https://www.linkedin.com/company/tunetx

Twitter: https://twitter.com/tunetx_news

Instagram: